Literature DB >> 33925370

Imbalance between Expression of FOXC2 and Its lncRNA in Lymphedema-Distichiasis Caused by Frameshift Mutations.

Sara Missaglia1,2, Daniela Tavian1,2, Sandro Michelini3, Paolo Enrico Maltese4, Andrea Bonanomi5, Matteo Bertelli4,6.   

Abstract

Forkhead-box C2 (FOXC2) is a transcription factor involved in lymphatic system development. FOXC2 mutations cause Lymphedema-distichiasis syndrome (LD). Recently, a natural antisense was identified, called lncRNA FOXC2-AS1, which increases FOXC2 mRNA stability. No studies have evaluated FOXC2 and FOXC2-AS1 blood expression in LD and healthy subjects. Here, we show that FOXC2 and FOXC-AS1 expression levels were similar in both controls and patients, and a significantly higher amount of both RNAs was observed in females. A positive correlation between FOXC2 and FOXC2-AS1 expression was found in both controls and patients, excluding those with frameshift mutations. In these patients, the FOXC2-AS1/FOXC2 ratio was about 1:1, while it was higher in controls and patients carrying other types of mutations. The overexpression or silencing of FOXC2-AS1 determined a significant increase or reduction in FOXC2 wild-type and frameshift mutant proteins, respectively. Moreover, confocal and bioinformatic analysis revealed that these variations caused the formation of nuclear proteins aggregates also involving DNA. In conclusion, patients with frameshift mutations presented lower values of the FOXC2-AS1/FOXC2 ratio, due to a decrease in FOXC2-AS1 expression. The imbalance between FOXC2 mRNA and its lncRNA could represent a molecular mechanism to reduce the amount of FOXC2 misfolded proteins, protecting cells from damage.

Entities:  

Keywords:  FOXC2; Lymphedema-distichiasis syndrome; confocal analysis; gene expression; lncRNA FOXC2-AS1; nuclear aggregates

Year:  2021        PMID: 33925370     DOI: 10.3390/genes12050650

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  28 in total

1.  Lymphoedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations.

Authors:  Carolyn Sholto-Douglas-Vernon; Rachel Bell; Glen Brice; Sahar Mansour; Mansoor Sarfarazi; Anne H Child; Alberto Smith; Russell Mellor; Kevin Burnand; Peter Mortimer; Steve Jeffery
Journal:  Hum Genet       Date:  2005-05-20       Impact factor: 4.132

2.  Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.

Authors:  Konstantin I Ivanov; Yan Agalarov; Leena Valmu; Olga Samuilova; Johanna Liebl; Nawal Houhou; Hélène Maby-El Hajjami; Camilla Norrmén; Muriel Jaquet; Naoyuki Miura; Nadine Zangger; Seppo Ylä-Herttuala; Mauro Delorenzi; Tatiana V Petrova
Journal:  Mol Cell Biol       Date:  2013-07-22       Impact factor: 4.272

3.  Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.

Authors:  Chun-Lin Zhang; Kun-Peng Zhu; Xiao-Long Ma
Journal:  Cancer Lett       Date:  2017-03-16       Impact factor: 8.679

Review 4.  The long noncoding RNA Malat1: Its physiological and pathophysiological functions.

Authors:  Xuejing Zhang; Milton H Hamblin; Ke-Jie Yin
Journal:  RNA Biol       Date:  2017-10-06       Impact factor: 4.652

5.  Clinical heterogeneity in lymphoedema-distichiasis with FOXC2 truncating mutations.

Authors:  R P Erickson; S L Dagenais; M S Caulder; C A Downs; G Herman; M C Jones; W S Kerstjens-Frederikse; A C Lidral; M McDonald; C C Nelson; M Witte; T W Glover
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

6.  Genetic Screening in a Large Cohort of Italian Patients Affected by Primary Lymphedema Using a Next Generation Sequencing (NGS) Approach.

Authors:  S Michelini; A Vettori; P E Maltese; M Cardone; A Bruson; A Fiorentino; F Cappellino; V Sainato; G Guerri; G Marceddu; S Tezzele; M Bertelli
Journal:  Lymphology       Date:  2016-06       Impact factor: 1.286

7.  Expression of FOXC2, PinX1, Ki-67 and Cyclin D1 in cutaneous cell carcinoma.

Authors:  Haiying Zhao; Yunfeng Cao; Guoqiang Wang; Zengxiang Luo
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

8.  Crystal Structure of FOXC2 in Complex with DNA Target.

Authors:  Shichang Li; Lagnajeet Pradhan; Shayan Ashur; Anshu Joshi; Hyun-Joo Nam
Journal:  ACS Omega       Date:  2019-06-24

9.  A novel PNPLA2 mutation causing total loss of RNA and protein expression in two NLSDM siblings with early onset but slowly progressive severe myopathy.

Authors:  Daniela Tavian; Lorenzo Maggi; Marina Mora; Lucia Morandi; Cinzia Bragato; Sara Missaglia
Journal:  Genes Dis       Date:  2019-07-29

10.  Long Noncoding RNAs CARMN, LUCAT1, SMILR, and MALAT1 in Thoracic Aortic Aneurysm: Validation of Biomarkers in Clinical Samples.

Authors:  Vaiva Patamsytė; Giedrius Žukovas; Dovydas Gečys; Diana Žaliaduonytė; Povilas Jakuška; Rimantas Benetis; Vaiva Lesauskaitė
Journal:  Dis Markers       Date:  2020-06-17       Impact factor: 3.434

View more
  2 in total

Review 1.  Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective.

Authors:  Kristian M Hargadon; Travis B Goodloe; Nathaniel D Lloyd
Journal:  Cancer Metastasis Rev       Date:  2022-06-14       Impact factor: 9.264

2.  Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways.

Authors:  Gabriele Bonetti; Stefano Paolacci; Michele Samaja; Paolo Enrico Maltese; Sandro Michelini; Serena Michelini; Silvia Michelini; Maurizio Ricci; Marina Cestari; Astrit Dautaj; Maria Chiara Medori; Matteo Bertelli
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.